A Phase 2 interventional study of Semaglutide and Placebo in Type 1 Diabetes and Obesity, sponsored by Viral N. Shah. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-03.
Sponsored by Viral N. Shah · Phase 2, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing semaglutide in Diabetes Mellitus, Type 1 — 11 open to participants now, 12 under way, 7 of them phase 3. Semaglutide · Diabetes Mellitus, Type 1.
Among the 16 studies testing semaglutide in Diabetes Mellitus, Type 1, this one is the 5th largest by enrollment, is one of 3 that started in 2023, is one of 4 in phase 2, and was the 5th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →11 of the 16 studies testing semaglutide in Diabetes Mellitus, Type 1 are open now, in 4 countries. Recruiting first, the newest first:
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18–65
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Steno Diabetes Center Copenhagen · Sites in Denmark
Ages 40–90
Vanderbilt University Medical Center · Sites in United States
Ages 12–50
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 9 · Phase 3 8 · Phase 4 1
First in 2019; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 115 is above the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 60 across the 16 interventional studies. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 16 has an industry lead sponsor. The 10 most frequent:
Viral N. Shah is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Viral N. Shah has 2 studies filed under Diabetes Mellitus, Type 1 — fewer than ten, so there is no comparison to draw.
4 of the studies testing semaglutide in Diabetes Mellitus, Type 1 that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06894784Phase 3McGill University Health Centre/Research Institute of the McGill University Health CentreA Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes | 2027-01 |
| NCT05819138Phase 3University of Colorado, DenverType 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes | 2027-10-01 |
| NCT06338553Vanderbilt University Medical CenterGLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab | 2027-03 |
| NCT05822609University of WashingtonTrial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies testing semaglutide in Diabetes Mellitus, Type 1, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the use of once weekly semaglutide injection in inadequately controlled obese adults with type 1 diabetes (T1D) using FDA-approved hybrid closed-loop therapies.
After being informed about the study and potential risks, all patients given written informed consent will undergo a 2-week screening period to determine eligibility for study entry. At week 0, patients who meet the eligibility requirements will be randomized in a double-blind manner using computer generated randomization scheme to receive either semaglutide or placebo (1:1 ratio) for 26 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For an eligible subject, all inclusion criteria must be answered "yes"
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive semaglutide once weekly injection in addition to their standard closed-loop therapy
Drug: Semaglutide
Participants in this group will receive placebo once weekly injection in addition to their standard closed-loop therapy
Drug: Placebo
Semaglutide up to 1 mg per week in addition to standard closed-loop therapy
Injection placebo up to 1 mg per week in addition to standard closed-loop therapy
Proportion of Adults With T1D Achieving Composite Outcome (CGM-measured Time in Range (TIR)>70% With Time Below Range (TBR) of <4% and Reduction in Body Weight by 5%) at 26 Weeks in the Semaglutide Group Compared to Placebo Group
Primary outcome will be analyzed per statistical analysis plan using intention to treat basis.
Time frame: 26 weeks
Change in HbA1c
HbA1c will be measured at a central laboratory and change in Hba1c from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.
Time frame: 26 weeks
Change in Mean Glucose
Mean glucose (mg/dL) will be obtained by CGM and change in mean CGM glucose from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.
Time frame: 26 weeks
Percent Time Spent in CGM-measured Glucose Range of 70-140 mg/dL (Time in Tight Target Range; TTIR)
Percent of time spent in tight glucose range (70-140 mg/dL) will be obtained by CGM and change in percent time in range from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.
Time frame: 26 weeks
Percent Time Spent in CGM-measured Glucose >180 mg/dL
Percent of time spent in glucose range \>180 mg/dL will be obtained by CGM and change in mean CGM glucose from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.
Time frame: 26 weeks
Percent Time Spent in CGM-measured Glucose >250mg/dL
Percent of time spent in glucose range \>250 mg/dL will be obtained by CGM and change in mean CGM glucose from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.
Time frame: 26 weeks
Percent Time Spent in CGM-measured Glucose <70mg/dL
Percent of time spent in glucose range \<70 mg/dL will be obtained by CGM and change in mean CGM glucose from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.
Time frame: 26 weeks
Change in CGM Measured Glycemic Variability (Coefficient of Variation)
Glucose coefficient of variation (mg/dL) will be obtained by CGM and change in glucose CV from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.
Time frame: 26 weeks
Change in Weight
The change in kg of body weight from baseline to 26 weeks will be compared by randomization group using an ITT analysis.
Time frame: 26 weeks
Change in BMI (Kg/m2)
Change in body mass index (BMI) calculated as kg body weight per meter squared of height from baseline to 26 weeks will be compared by randomization group using an ITT analysis.
Time frame: 26 weeks
Severe Hypoglycemia
SH events in number of patients per group
Time frame: 26 weeks
Change in Patient Reported Quality of Life
Patient reported quality of life will be measured using a validated instrument (ADDQOL) and the change in score from baseline to 26 weeks will be compared by randomization group using an ITT analysis.
Time frame: 26 weeks
Proportion of Participants With HbA1c <7%
proportion (N, %) of participants achieving HbA1c \<7% between two groups over 26 weeks
Time frame: 26 weeks
Proportion of Participants With HbA1c <7.5%
proportion (N, %) of participants achieving HbA1c \<7.5% between two groups over 26 weeks
Time frame: 26 weeks
HbA1c Improvement
HbA1c improvement from baseline to 26 weeks between two groups
Time frame: 26 weeks
HbA1c Improvement of >0.4% From Baseline
proportion of participants with HbA1c improvement of \>0.4% from baseline between two groups
Time frame: 26 weeks
Proportion of Participants Achieving TIR >70%
Proportion of participants achieving TIR \>70% between two groups over 26 weeks
Time frame: 26 weeks
Proportion of Participants Achieving TITR >50%
Proportion of participants achieving TITR (time in 70-140 mg/dL) \>50% between two groups
Time frame: 26 weeks
Proportion of Participants Achieving TIR >80%
Proportion of participants achieving TIR \>80% between two groups
Time frame: 26 weeks
Proportion of Participants Achieving TITR >60%
Proportion of participants achieving TITR (time in 70-140 mg/dL) \>60% between two groups
Time frame: 26 weeks
Number of TBR<70 Events
Numbers of events of CGM glucose \<70 mg/dL lasting for at least 15 minutes between two groups
Time frame: 26 weeks
Number of TBR <54 Events
Numbers of events of CGM glucose \<54mg/dL lasting for at least 15 minutes between two groups
Time frame: 26 weeks
Change in Total Daily Dose of Insulin (TDD, Units Per Day and U/Kg/Day)
Change in TDD between two groups
Time frame: 26 weeks
Proportion Achieving Weight Loss ≥5%
Proportion of participants achieving weight loss ≥5% from baseline between two groups
Time frame: 26 weeks
Proportion Achieving Weight Loss ≥10%
Proportion of participants achieving weight loss ≥10% from baseline between two groups
Time frame: 26 weeks
Proportion of Achieving BMI <30 kg/m2
Proportion of participants achieving BMI \<30 kg/m2 between two groups
Time frame: 26 weeks
Proportion of Achieving BMI <25 kg/m2
Proportion of participants achieving BMI \<25 kg/m2 between two groups
Time frame: 26 weeks
Change in Systolic Blood Pressure (SBP)
change in SBP (mmHg) between two groups
Time frame: 26 weeks
Change in Diastolic Blood Pressure (DBP)
change in DBP (mmHg) between two groups
Time frame: 26 weeks
Change in Pulse Pressure
change in pulse pressure between two groups
Time frame: 26 weeks
Change in Triglyceride/HDL Ratio
Change in triglyceride/HDL ratio between two groups
Time frame: 26 weeks
Change in Brach D
Change in brachial arterial distensibility between two groups
Time frame: 26 weeks
Change in Carotid Intima Media Thickness (cIMT)
Change in carotid intima media thickness (cIMT) between two groups
Time frame: 26 weeks
Change in Femoral to Carotid Pulse Wave Velocity (m/s)
Change in femoral to carotid pulse wave velocity (m/s) between two groups
Time frame: 26 weeks
Change in Urine Albumin to Creatinine Ratio (ACR)
Change in ACR between two groups
Time frame: 26 weeks
Quality of Life (Diabetes Dependent QOL)
Change in QOL between two groups
Time frame: 26 weeks
Change in CGM Metrics by Daytime vs Nighttime
Change in CGM metrics (TIR, TITR, mean glucose, TBR, TAR \>180, SD, CV) by daytime (6 AM to \<11 PM) and nighttime (11 PM to \<6 AM) between two groups
Time frame: 26 weeks
AID Setting Adjustment
Defined any adjustment in settings by provider or patient per person over the study period by two groups (number of adjustments (N) during trial) between two groups
Time frame: 26 weeks
Change in Basal Insulin Per Day
Change in basal insulin per day (Total basal insulin including autobasal delivery, units per day and U/kg/day) between two groups
Time frame: 26 weeks
Change in Total Boluses Per Day
Change in total boluses per day (frequency of boluses per day) between two groups
Time frame: 26 weeks
Achievement of Primary Outcome and Key Secondary Outcomes by Types of AID Systems
Proportion of participants achieving primary outcome and key secondary glycemic outcomes by types of AID systems
Time frame: 26 weeks
Change in Carbohydrate Intake Per Day (Grams/Day)
Change in Carbohydrate intake per day (grams/day) between two groups
Time frame: 26 weeks
Change in Total Bolus Insulin Per Day
Change in total bolus insulin per day (units per day and U/Kg/day) between two groups
Time frame: 26 weeks
Change in eGFR
Change in eGFR using CKD-EPI between two groups
Time frame: 26 weeks
Change in Fib-4 Score
Change in Fib-4 score between two groups
Time frame: 26 weeks
Change in HSI (Hepatic Steatosis Index)
Change in HSI (hepatic steatosis index) between two groups
Time frame: 26 weeks
Change in MRI Measured Pulse Wave Velocity and Longitudinal Strain
Change in MRI measured pulse wave velocity and longitudinal strain between two groups
Time frame: 26 weeks
Change in LDL-C
Change in LDL-C between two groups
Time frame: 26 weeks
Change in TC
Change in TC between two groups
Time frame: 26 weeks
Change in TG
Change in TG between two groups
Time frame: 26 weeks
Change in HDL-C
Change in HDL-C between two groups
Time frame: 26 weeks
Proportion With ACR <30 at 26 Weeks
Proportion of participants with ACR \<30 at 26 weeks between two groups
Time frame: 26 weeks
Proportion With Change in ACR From >30 to <30
Proportion of participants with change in ACR from \>30 to \<30 between two groups
Time frame: 26 weeks
Achievement of Primary Outcomes by Baseline BMI (BMI <35 vs >35)
Achievement of primary outcomes by baseline BMI (BMI \<35 vs \>35)
Time frame: 26 weeks
Achievement of Primary Outcomes by Baseline A1c (A1c <7.5% vs >7.5%)
Achievement of primary outcomes by baseline A1c (A1c \<7.5% vs \>7.5%)
Time frame: 26 weeks
| Milestone | Semaglutide | Control |
|---|---|---|
| Started | 36 | 36 |
| Completed | 34 | 33 |
| Not completed | 2 | 3 |
Primary outcome will be analyzed per statistical analysis plan using intention to treat basis.
| Participants | Semaglutide | Control |
|---|---|---|
| Proportion of Adults With T1D Achieving Composite Outcome (CGM-measured Time in Range (TIR)>70% With Time Below Range (TBR) of <4% and Reduction in Body Weight by 5%) at 26 Weeks in the Semaglutide Group Compared to Placebo Group | 13 | 0 |
HbA1c will be measured at a central laboratory and change in Hba1c from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.
| percentage HbA1c | Semaglutide | Control |
|---|---|---|
| Change in HbA1c | -0.7 ± 0.1 | -0.4 ± 0.1 |
Mean glucose (mg/dL) will be obtained by CGM and change in mean CGM glucose from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.
| mg/dL | Semaglutide | Control |
|---|---|---|
| Change in Mean Glucose | -15.7 ± 2.6 | -3.6 ± 2.8 |
Percent of time spent in tight glucose range (70-140 mg/dL) will be obtained by CGM and change in percent time in range from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.
| percentage of time | Semaglutide | Control |
|---|---|---|
| Percent Time Spent in CGM-measured Glucose Range of 70-140 mg/dL (Time in Tight Target Range; TTIR) | 9.8 ± 1.7 | 2.9 ± 1.8 |
Percent of time spent in glucose range \>180 mg/dL will be obtained by CGM and change in mean CGM glucose from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.
| percentage | Semaglutide | Control |
|---|---|---|
| Percent Time Spent in CGM-measured Glucose >180 mg/dL | -11.1 ± 1.8 | -2.7 ± 1.9 |
Percent of time spent in glucose range \>250 mg/dL will be obtained by CGM and change in mean CGM glucose from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.
| percentage | Semaglutide | Control |
|---|---|---|
| Percent Time Spent in CGM-measured Glucose >250mg/dL | -5.1 ± 1.1 | -0.5 ± 1.2 |
Percent of time spent in glucose range \<70 mg/dL will be obtained by CGM and change in mean CGM glucose from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.
| percentage | Semaglutide | Control |
|---|---|---|
| Percent Time Spent in CGM-measured Glucose <70mg/dL | 0.1 ± 0.2 | 0.4 ± 0.2 |
Glucose coefficient of variation (mg/dL) will be obtained by CGM and change in glucose CV from baseline to 26 weeks will be compared by randomization group using intention to treat (ITT) analysis.
| percentage | Semaglutide | Control |
|---|---|---|
| Change in CGM Measured Glycemic Variability (Coefficient of Variation) | -0.3 ± 0.8 | 0.9 ± 0.9 |
The change in kg of body weight from baseline to 26 weeks will be compared by randomization group using an ITT analysis.
| kg | Semaglutide | Control |
|---|---|---|
| Change in Weight | -9.2 ± 0.7 | -0.4 ± 0.6 |
Change in body mass index (BMI) calculated as kg body weight per meter squared of height from baseline to 26 weeks will be compared by randomization group using an ITT analysis.
| kg/m2 | Semaglutide | Control |
|---|---|---|
| Change in BMI (Kg/m2) | -3.3 ± 0.3 | -0.2 ± 0.2 |
SH events in number of patients per group
| Participants | Semaglutide | Control |
|---|---|---|
| Severe Hypoglycemia | 2 | 2 |
Patient reported quality of life will be measured using a validated instrument (ADDQOL) and the change in score from baseline to 26 weeks will be compared by randomization group using an ITT analysis.
Results for this outcome have not been posted.
proportion (N, %) of participants achieving HbA1c \<7% between two groups over 26 weeks
Results for this outcome have not been posted.
proportion (N, %) of participants achieving HbA1c \<7.5% between two groups over 26 weeks
Results for this outcome have not been posted.
HbA1c improvement from baseline to 26 weeks between two groups
Results for this outcome have not been posted.
proportion of participants with HbA1c improvement of \>0.4% from baseline between two groups
Results for this outcome have not been posted.
Proportion of participants achieving TIR \>70% between two groups over 26 weeks
Results for this outcome have not been posted.
Proportion of participants achieving TITR (time in 70-140 mg/dL) \>50% between two groups
Results for this outcome have not been posted.
Proportion of participants achieving TIR \>80% between two groups
Results for this outcome have not been posted.
Proportion of participants achieving TITR (time in 70-140 mg/dL) \>60% between two groups
Results for this outcome have not been posted.
Numbers of events of CGM glucose \<70 mg/dL lasting for at least 15 minutes between two groups
Results for this outcome have not been posted.
Numbers of events of CGM glucose \<54mg/dL lasting for at least 15 minutes between two groups
Results for this outcome have not been posted.
Change in TDD between two groups
Results for this outcome have not been posted.
Proportion of participants achieving weight loss ≥5% from baseline between two groups
Results for this outcome have not been posted.
Proportion of participants achieving weight loss ≥10% from baseline between two groups
Results for this outcome have not been posted.
Proportion of participants achieving BMI \<30 kg/m2 between two groups
Results for this outcome have not been posted.
Proportion of participants achieving BMI \<25 kg/m2 between two groups
Results for this outcome have not been posted.
change in SBP (mmHg) between two groups
Results for this outcome have not been posted.
change in DBP (mmHg) between two groups
Results for this outcome have not been posted.
change in pulse pressure between two groups
Results for this outcome have not been posted.
Change in triglyceride/HDL ratio between two groups
Results for this outcome have not been posted.
Change in brachial arterial distensibility between two groups
Results for this outcome have not been posted.
Change in carotid intima media thickness (cIMT) between two groups
Results for this outcome have not been posted.
Change in femoral to carotid pulse wave velocity (m/s) between two groups
Results for this outcome have not been posted.
Change in ACR between two groups
Results for this outcome have not been posted.
Change in QOL between two groups
Results for this outcome have not been posted.
Change in CGM metrics (TIR, TITR, mean glucose, TBR, TAR \>180, SD, CV) by daytime (6 AM to \<11 PM) and nighttime (11 PM to \<6 AM) between two groups
Results for this outcome have not been posted.
Defined any adjustment in settings by provider or patient per person over the study period by two groups (number of adjustments (N) during trial) between two groups
Results for this outcome have not been posted.
Change in basal insulin per day (Total basal insulin including autobasal delivery, units per day and U/kg/day) between two groups
Results for this outcome have not been posted.
Change in total boluses per day (frequency of boluses per day) between two groups
Results for this outcome have not been posted.
Proportion of participants achieving primary outcome and key secondary glycemic outcomes by types of AID systems
Results for this outcome have not been posted.
Change in Carbohydrate intake per day (grams/day) between two groups
Results for this outcome have not been posted.
Change in total bolus insulin per day (units per day and U/Kg/day) between two groups
Results for this outcome have not been posted.
Change in eGFR using CKD-EPI between two groups
Results for this outcome have not been posted.
Change in Fib-4 score between two groups
Results for this outcome have not been posted.
Change in HSI (hepatic steatosis index) between two groups
Results for this outcome have not been posted.
Change in MRI measured pulse wave velocity and longitudinal strain between two groups
Results for this outcome have not been posted.
Change in LDL-C between two groups
Results for this outcome have not been posted.
Change in TC between two groups
Results for this outcome have not been posted.
Change in TG between two groups
Results for this outcome have not been posted.
Change in HDL-C between two groups
Results for this outcome have not been posted.
Proportion of participants with ACR \<30 at 26 weeks between two groups
Results for this outcome have not been posted.
Proportion of participants with change in ACR from \>30 to \<30 between two groups
Results for this outcome have not been posted.
Achievement of primary outcomes by baseline BMI (BMI \<35 vs \>35)
Results for this outcome have not been posted.
Achievement of primary outcomes by baseline A1c (A1c \<7.5% vs \>7.5%)
Results for this outcome have not been posted.
Collected over from signing consent from till end of the study (i.e 26 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Semaglutide | 0/36 (0%) | 1/36 (2.8%) | 26/36 (72.2%) |
| Control | 0/36 (0%) | 0/36 (0%) | 11/36 (30.6%) |
| Event | Semaglutide | Control |
|---|---|---|
| Nausea & vomitingGastrointestinal disorders | 1/36 | 0/36 |
| Event | Semaglutide | Control |
|---|---|---|
| Gastrointestinal eventsGastrointestinal disorders | 19/36 | 9/36 |
| COVID-19Infections and infestations | 4/36 | 1/36 |
| Upper respitory infectinInfections and infestations | 3/36 | 1/36 |
| Age, Continuous(years) | Semaglutide | Control | Total |
|---|---|---|---|
| Mean | 41.4 ± 11.6 | 38.9 ± 13.1 | 40 ± 12 |
| Sex: Female, Male(Participants) | Semaglutide | Control | Total |
|---|---|---|---|
| Female | 22 | 20 | 42 |
| Male | 14 | 16 | 30 |
| Ethnicity (NIH/OMB)(Participants) | Semaglutide | Control | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 4 | 5 |
| Not Hispanic or Latino | 35 | 32 | 67 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Semaglutide | Control | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 3 | 6 |
| White | 33 | 30 | 63 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 2 |
| body mass index(kg/m2) | Semaglutide | Control | Total |
|---|---|---|---|
| Mean | 34.7 ± 3.9 | 36.0 ± 5.2 | 35 ± 4.5 |
| HbA1c(%) | Semaglutide | Control | Total |
|---|---|---|---|
| Mean | 7.8 ± 0.6 | 7.7 ± 0.6 | 7.8 ± 0.6 |
| Diabetes Duration(years) | Semaglutide | Control | Total |
|---|---|---|---|
| Mean | 23.4 ± 11.2 | 21.9 ± 11.6 | 23 ± 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — IPD may be available once the study is completed and all results are published.
Ran from Apr 2023 to primary completion in Aug 2024, 15 months.
Results were first posted in Aug 2025, 1 year after primary completion.
Of 83 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's 15 months is below that.
Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide
Viral N. Shah